NCT06148142Completed
Effectiveness of a Community Pharmacy-based Health Promotion Program on Hypertension in Bangladesh and Pakistan
Effectiveness of a Community Pharmacy-based Health Promotion Program on Hypertension in Bangladesh and Pakistan: Study Protocol for a Cluster Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 22 Jul 2025
Brief summary (registry, in English)
The aim of this multi-country research project is to reduce the blood pressure of individuals with hypertension over a 18-month period in Bangladesh and Pakistan. A cluster randomized controlled trial (cRCT) will be conducted with two arms. The estimated sample size is around 3600 hypertensive adults. Bangladesh study participants will consist of 3600 hypertensive individuals. Approximately 10% of participants will be selected based on Bangladesh samples from Pakistan (360 hypertensive patients, four pharmacies). Community pharmacies will be randomised to one of two parallel groups (allocation ratio 1:1). Pharmacy professionals will provide educational training and counselling, as well as phone calls/mobile text messages and care coordination in the health sector as part of the intervention. The study will be conducted in three phases: baseline survey; intervention and follow-up; and endline survey with impact evaluation. The primary outcome will be BP reduction and the secondary outcomes will be BP controlled to target, treatment adherence, mortality or hospital admission rates resulting from hypertension and its related complications, incremental cost per quality-adjusted life year gained, improvement in knowledge on healthy lifestyle, change in dietary salt intake, and change in prevalence of current smokers.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 3600 (actual)
- First submitted
- 7 Nov 2023
- Start date
- 1 Jun 2023
- Primary completion date
- 30 Jun 2025
- Lead sponsor
- Hitotsubashi University
- Diseases
- High blood pressure
- NCT number
- NCT06148142
What you commit to
- Study type: Interventional
- Participants enrolled: 3600
- From 1 Jun 2023 to the primary completion date, 30 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Individuals with advanced medical disease
- Those having cognitive and psychiatric problems,
Other
- Pregnant and lactating women
- Involvement in any other interventional study
- Individuals who are unable to give informed consent.
Who the study is looking for
- Aged 18 years to 90 years old
- Hypertensive (SBP ≥140 mmHg and DBP ≥90 mmHg and/or taking antihypertensive medications)
- Having suboptimal medication adherence to antihypertensive drugs
- Capable of communicating verbally in local language
- Permanent resident of the study area
- Access to mobile phone
- Consent to participate
- Pharmacists' inclusion criteria include:
- Ensuring a sufficient amount of time to implement intervention on hypertensive participants
- Consent to participate
- Able to operate smartphone or tablet.
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Global Public Health Research Foundation Coordinator of this site? Confirm its status | Dhaka | Bangladesh | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.